LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 261

Suchoptionen

  1. Artikel ; Konferenzbeitrag: FAECAL MICROBIOTA TRANSPLANTATION IS A SIMPLE, EFFECTIVE AND SAFE TREATMENT IN THE MANAGEMENT OF C. DIFFICILE INFECTION IN DAILY CLINICAL PRACTICE

    El Hajra Martinez, I. / Ferre Aracil, C. / Vera Mendoza, M.I. / Ramos Martínez, A. / Muñez Rubio, E. / Fernández-Cruz, A. / Matallana Royo, V. / Garcia Maseda, S. / Sanchez Romero, I. / Martinez Ruiz, R. / Blanco Rey, S. / Santos Perez, E. / Pinto Da Costa, A. / Calleja Panero, J.L.

    Endoscopy

    2022  Band 54, Heft S 01

    Veranstaltung/Kongress ESGE Days 2022, Prague, Czech Republic, 2022-04-28
    Sprache Englisch
    Erscheinungsdatum 2022-04-01
    Verlag Georg Thieme Verlag KG
    Erscheinungsort Stuttgart ; New York
    Dokumenttyp Artikel ; Konferenzbeitrag
    ZDB-ID 80120-3
    ISSN 1438-8812 ; 0013-726X
    ISSN (online) 1438-8812
    ISSN 0013-726X
    DOI 10.1055/s-0042-1744878
    Datenquelle Thieme Verlag

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Improving access to SLE therapies in low and middle-income countries.

    Mendoza-Pinto, Claudia / Etchegaray-Morales, Ivet / Ugarte-Gil, Manuel F

    Rheumatology (Oxford, England)

    2023  Band 62, Heft Suppl 1, Seite(n) i30–i35

    Abstract: SLE increases disease burden in those affected with it, and that is particularly the case in low- and middle-income countries. The 2019 Addressing Lupus Pillar of Health Advancement project is a multiphase initiative whose objective is to recognize, ... ...

    Abstract SLE increases disease burden in those affected with it, and that is particularly the case in low- and middle-income countries. The 2019 Addressing Lupus Pillar of Health Advancement project is a multiphase initiative whose objective is to recognize, hierarchize and establish approaches for diligent SLE research, care and access to healthcare. Lack of access to high-cost medications that have been shown to be efficacious in the short term and that potentially reduce damage in SLE is a complex issue. In this review, we highlight opportunities and plans of action to diminish costs and improve access to therapies, which should be recognized and executed, preferably within regional strategies with multiple stakeholders (including supranational organizations, governments, the pharmaceutical industry, medical societies and the general population) connected with and grounded in structured and clear cost-effectiveness analysis.
    Mesh-Begriff(e) Humans ; Developing Countries ; Delivery of Health Care ; Cost of Illness ; Lupus Erythematosus, Systemic/drug therapy
    Sprache Englisch
    Erscheinungsdatum 2023-03-29
    Erscheinungsland England
    Dokumenttyp Review ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/keac530
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Genetic variation of FTO: rs1421085 T>C, rs8057044 G>A, rs9939609 T>A, and copy number (CNV) in Mexican Mayan school-aged children with obesity/overweight and with normal weight.

    González-Herrera, Lizbeth / Zavala-Castro, Jorge / Ayala-Cáceres, Claudia / Pérez-Mendoza, Gerardo / López-González, María José / Pinto-Escalante, Doris / Canto-Cetina, Thelma / García-Escalante, María Guadalupe / Rubi-Castellanos, Rodrigo / Contreras-Capetillo, Silvina / Herrera-Sanchez, Fernando / Méndez-Domínguez, Nina / Alcocer-Gamboa, Alberto

    American journal of human biology : the official journal of the Human Biology Council

    2018  Band 31, Heft 1, Seite(n) e23192

    Abstract: ... polymorphisms (SNPs) rs1421085T>C, rs9939609T>A, rs8057044G>A and copy number variation (CNV) was evaluated ...

    Abstract Objectives: Genetic variation of the fat mass and obesity associated gene (FTO) has been identified as a risk factor for obesity and obesity traits. Distribution of FTO single nutleotide polymorphisms (SNPs) rs1421085T>C, rs9939609T>A, rs8057044G>A and copy number variation (CNV) was evaluated in association with childhood obesity or overweight status in children with Mayan ethnicity.
    Methods: We included 318 school-aged children with obesity or overweight status (body mass index [BMI]: >85th percentile) and 303 children with normal weight (BMI: 15th-85th percentile). Genotyping was performed using real-time polymerase chain reaction (RT-PCR) with TaqMan probes. The cross-sectional study was carried out using univariate and multivariate logistic regression models adjusted for gender.
    Results: FTO-SNP rs1421085 showed significant differences between children with obesity and children with normal weight for the heterozygous genotype (P = 0.003) and for allele frequencies (P = 0.023). Adjusting by gender, significant differences were found in frequencies of the hetezygous genotype of SNPs rs9939609 (P = 0.023) and rs1421085 (P = 0.003) as well as in allele frequencies (P = 0.042 and P = 0.013, respectively) between girls with obesity and girls without obesity. In contrast, SNP rs8057044 was significantly different only between heterozygous overweight versus normal weight boys (P = 0.035) and for the allele frequency of rs8057044 (P = 0.021). The mean relative CNV was significantly higher in male overweight children than in boys with normal weight (P = 0.000).
    Conclusions: The FTO SNP rs1421085 is a genetic factor associated with obesity in Mayan school-aged children. FTO SNPs rs1421085 and rs9939609 affect genetic susceptibility for obesity only in girls, whereas, SNP rs8057044 and CNV are associated with overweight status only in boys.
    Mesh-Begriff(e) Adolescent ; Alpha-Ketoglutarate-Dependent Dioxygenase FTO/genetics ; Body Weight/genetics ; Child ; Child, Preschool ; Cross-Sectional Studies ; Female ; Genetic Variation ; Humans ; Indians, North American/statistics & numerical data ; Male ; Mexico/epidemiology ; Overweight/epidemiology ; Overweight/genetics ; Pediatric Obesity/epidemiology ; Pediatric Obesity/genetics ; Polymorphism, Single Nucleotide ; Risk Factors
    Chemische Substanzen Alpha-Ketoglutarate-Dependent Dioxygenase FTO (EC 1.14.11.33) ; FTO protein, human (EC 1.14.11.33)
    Sprache Englisch
    Erscheinungsdatum 2018-12-10
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1025339-7
    ISSN 1520-6300 ; 1042-0533
    ISSN (online) 1520-6300
    ISSN 1042-0533
    DOI 10.1002/ajhb.23192
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Risk of Diabetes Mellitus in systemic lupus erythematosus: systematic review and meta-analysis.

    Etchegaray-Morales, Ivet / Mendoza-Pinto, Claudia / Munguía-Realpozo, Pamela / Solis-Poblano, Juan Carlos / Méndez-Martínez, Socorro / Ayón-Aguilar, Jorge / Abud-Mendoza, Carlos / García-Carrasco, Mario / Cervera, Ricard

    Rheumatology (Oxford, England)

    2024  

    Abstract: Objective: To investigate the risk of DM and evaluate the impact of SLE therapies on the risk of developing DM in patients with SLE.: Methods: Electronic database searches of PubMed, Embase, Cochrane Library, and Web of Science were performed from ... ...

    Abstract Objective: To investigate the risk of DM and evaluate the impact of SLE therapies on the risk of developing DM in patients with SLE.
    Methods: Electronic database searches of PubMed, Embase, Cochrane Library, and Web of Science were performed from inception to February 2023. Cohort and cross-sectional studies that analyzed the risk of DM in patients with SLE were included. The associations between diabetes and antirheumatic agents, such as antimalarials and glucocorticoids, were analyzed in cohort studies. Data were pooled using fixed- or random-effects meta-analysis to estimate pooled odd ratios (OR), relative risks (RR), and 95% confidence intervals (CIs). This study was registered with PROSPERO (CRD42023402774).
    Results: A total of 37 studies (23 cross-sectional and 14 cohort studies) involving 266 537 patients with SLE were included. The pooled analyses from cross-sectional studies and cohort studies did not show an increased risk of DM in SLE patients (OR = 1.05, 95% CI 0.87-1.27; p = 0.63 and RR = 1.32, 95% CI 0.93-1.87; p= 0.12, respectively). However, several cohort studies consistently demonstrated a reduced risk of diabetes with antimalarials, while glucocorticoid use has been associated with an increased risk of developing diabetes. Age, sex, hypertension, and immunosuppressants have not been identified as risk factors for DM in SLE patients.
    Conclusions: Although there was no increased risk of DM in patients with SLE compared with controls, HCQ users or adherents had a decreased risk, whereas glucocorticoid users had an increased risk.
    Sprache Englisch
    Erscheinungsdatum 2024-03-29
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 1464822-2
    ISSN 1462-0332 ; 1462-0324
    ISSN (online) 1462-0332
    ISSN 1462-0324
    DOI 10.1093/rheumatology/keae204
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Predicting progression from undifferentiated connective tissue disease to definite connective tissue disease: A systematic review and meta-analysis.

    Dyball, Sarah / Rodziewicz, Mia / Mendoza-Pinto, Claudia / Bruce, Ian N / Parker, Ben

    Autoimmunity reviews

    2022  Band 21, Heft 11, Seite(n) 103184

    Abstract: Purpose: Undifferentiated connective tissue disease (UCTD) encapsulates a broad range of conditions including incomplete forms of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), some of whom progress to a formal clinical diagnosis over ... ...

    Abstract Purpose: Undifferentiated connective tissue disease (UCTD) encapsulates a broad range of conditions including incomplete forms of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), some of whom progress to a formal clinical diagnosis over time. This systematic review (SR) and meta-analysis aimed to identify clinical and laboratory features and biomarkers that can predict progression of UCTD.
    Methods: A systematic literature search was carried out on MEDLINE, EMBASE and the Cochrane Central Register of Randomized Controlled Trials. Abstracts and full-text manuscripts were screened by two reviewers. Publications were included if they included at least 20 UCTD patients, a minimum of six months of follow up, and provided data on at least one risk factor for developing a defined CTD. The QUIPS tool was used to assess risk of bias (RoB) and GRADE for grading the quality of the evidence. The study is registered with PROSPERO (ID: CRD42021237725).
    Results: Fifty-nine studies were included in the SR, and forty-one in the meta-analysis. The predictors for progression to SLE with the highest certainty of evidence included those with younger age (MD -5.96 [-11.05-0.87 years]), serositis (RR 2.69 [1.61-4.51]), or the presence of anti-dsDNA antibodies (RR 4.27 [1.92-9.51]). For SSc, the highest certainty of evidence included puffy fingers (RR [3.09 [1.48-6.43]), abnormal nailfold changes (NFC) (avascular areas [RR 5.71 (3.03-10.8)] or active or late SSc pattern [RR 2.24 (1.25-4.01)] and anti-topoisomerase-I (RR 1.83 [1.45-2.30]). No novel biomarkers were included in the meta-analysis; however HLA molecules, regulatory T cell shift, pro-inflammatory cytokines and complement activation products were identified as potential predictors for evolution of disease.
    Conclusions: Clinical and immunological parameters may predict which patients with UCTD progress to definitive disease; however, the heterogeneous nature and RoB in most studies limits the ability to apply these results in routine clinical practice. Limited data suggest that some novel biomarkers may provide additional predictive value but these will need larger well designed studies to fully delineate their clinical utility.
    Mesh-Begriff(e) Humans ; Undifferentiated Connective Tissue Diseases ; Connective Tissue Diseases/diagnosis ; Lupus Erythematosus, Systemic/diagnosis ; Scleroderma, Systemic ; Biomarkers ; Disease Progression
    Chemische Substanzen anti-dsDNA autoantibody ; Biomarkers
    Sprache Englisch
    Erscheinungsdatum 2022-08-27
    Erscheinungsland Netherlands
    Dokumenttyp Meta-Analysis ; Systematic Review ; Journal Article ; Review
    ZDB-ID 2144145-5
    ISSN 1873-0183 ; 1568-9972
    ISSN (online) 1873-0183
    ISSN 1568-9972
    DOI 10.1016/j.autrev.2022.103184
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Predictors and prognostic factors influencing outcomes of anti-CD20 monoclonal antibodies in systemic lupus erythematosus: A systematic review update.

    Rodziewicz, Mia / Mendoza-Pinto, Claudia / Dyball, Sarah / Munguía-Realpozo, Pamela / Parker, Ben / Bruce, Ian N

    Seminars in arthritis and rheumatism

    2023  Band 65, Seite(n) 152346

    Abstract: Background: Anti-C20 monoclonal antibodies (MAb), such as rituximab, are commonly used for the treatment of patients with severe or refractory systemic lupus erythematosus (SLE) but clinical outcomes are highly variable. We aimed to provide an update of ...

    Abstract Background: Anti-C20 monoclonal antibodies (MAb), such as rituximab, are commonly used for the treatment of patients with severe or refractory systemic lupus erythematosus (SLE) but clinical outcomes are highly variable. We aimed to provide an update of a systematic review of predictive and prognostic factors of anti-CD20 MAb treatment in SLE.
    Methods: A systematic literature search was undertaken to identify predictive and prognostic factors of clinical response following treatment with anti-CD20 therapies in SLE patients. Studies examining rituximab published prior to 2015 were excluded. Risk of bias was assessed for randomized controlled trials (RCTs) using the Cochrane Collaboration (RoB2) tool for RCTs and the Quality In Prognosis Studies Tool (QUIPS) for cohort studies. A narrative synthesis of the evidence was undertaken and quality of evidence (QoE) was assessed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
    Results: From 850 studies identified, 17 studies met the inclusion criteria. A further 8 studies were identified and included through search updates. There were two post-hoc analyses of RCTs of rituximab, one RCT of ocrelizumab and one of obinutuzumab; and 16 cohort studies examining rituximab treatment. The overall QoE was low or very low. There was wide heterogeneity in definitions of clinical disease activity and outcome measures, non-standardized laboratory cut-offs, failure to account for confounders and multiple subgroup analyses of differing outcomes. B cell depletion as well as novel biomarkers, such as S100 proteins, FCGR genotype, anti-vimentin and anti-drug antibodies showed some evidence of prognostic value but QoE was limited due to moderate to high risk of bias, early phase of investigation and imprecision of results.
    Conclusion: There has been no validation of previously identified prognostic factors to guide outcome in anti-CD20 treated lupus patients. Hypothesis-driven studies of several novel markers however, demonstrate prognostic value and require replication and validation to support their use in routine clinical practice.
    Prospero registration number: CRD42020220339.
    Mesh-Begriff(e) Humans ; Rituximab/therapeutic use ; Treatment Outcome ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/adverse effects ; Lupus Erythematosus, Systemic/drug therapy ; Lupus Erythematosus, Systemic/chemically induced
    Chemische Substanzen Rituximab (4F4X42SYQ6) ; Antibodies, Monoclonal ; Antineoplastic Agents
    Sprache Englisch
    Erscheinungsdatum 2023-12-16
    Erscheinungsland United States
    Dokumenttyp Systematic Review ; Journal Article ; Review
    ZDB-ID 120247-9
    ISSN 1532-866X ; 0049-0172
    ISSN (online) 1532-866X
    ISSN 0049-0172
    DOI 10.1016/j.semarthrit.2023.152346
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Health related quality of life in Mexican women with systemic lupus erythematosus: a descriptive study using SF-36 and LupusQoL(C).

    García-Carrasco, M / Mendoza-Pinto, C / Cardiel, M H / Méndez-Martínez, S / García-Villaseñor, A / Jiménez-Hernández, C / Alonso-García, N E / Briones-Rojas, R / Ramos-Álvarez, G / López-Colombo, A

    Lupus

    2012  Band 21, Heft 11, Seite(n) 1219–1224

    Abstract: The LupusQoL© questionnaire is a disease-specific health related quality of life (HRQOL) instrument for adults with systemic lupus erythematosus (SLE). The Short Form-36 (SF-36) is a generic instrument that captures the physical, psychological, and ... ...

    Abstract The LupusQoL© questionnaire is a disease-specific health related quality of life (HRQOL) instrument for adults with systemic lupus erythematosus (SLE). The Short Form-36 (SF-36) is a generic instrument that captures the physical, psychological, and social impact. We conducted a descriptive study of women aged ≥ 18 years attending our Lupus Clinic. HRQOL was assessed by applying the LupusQoL© and SF-36. Lupus activity was measured using the Mexican Systemic Lupus Erythematosus Disease Activity Index (Mex-SLEDAI) and chronic damage using the Systemic Lupus Collaborative Clinics Damage Index (SDI). Data were analyzed using descriptive statistics, the chi-square test and Pearson's product moment correlation coefficient. A total of 127 patients were included with a mean age of 40.5 ± 12.6 years. The mean disease duration was 8.2 ± 5.6 years, the mean disease activity score was 2.4 ± 3.0, and the mean SDI score 0.77 ± 1.06. The mean SF-36 score was 58.1 ± 21.1 and the mean LupusQoL© score was 69 ± 22.7. The correlation between global scores of the SF-36 and LupusQoL© was rho = 0.73 (p < 0.001). The correlation between lupus disease activity and the SF-36 and the LupusQoL© was -0.26 (p = 0.003) and -0.25 (p = 0.004), respectively. The correlation between the SDI and the SF-36 and the LupusQoL© was -0.28 (p = 0.001) and -0.38 (p < 0.0001), respectively. In conclusions: both LupusQoL© and SF-36 were useful instruments in assessing HRQOL in Mexican lupus female patients. The usefulness of the LupusQoL© should be evaluated in lupus patients with moderate to severe disease activity.
    Mesh-Begriff(e) Adult ; Chi-Square Distribution ; Cross-Sectional Studies ; Data Interpretation, Statistical ; Female ; Humans ; Lupus Erythematosus, Systemic/physiopathology ; Middle Aged ; Quality of Life ; Severity of Illness Index ; Surveys and Questionnaires
    Sprache Englisch
    Erscheinungsdatum 2012-10
    Erscheinungsland England
    Dokumenttyp Comparative Study ; Journal Article
    ZDB-ID 1154407-7
    ISSN 1477-0962 ; 0961-2033
    ISSN (online) 1477-0962
    ISSN 0961-2033
    DOI 10.1177/0961203312456749
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: The Cardio-Rheumatology Approach to Atherosclerotic Cardiovascular Disease.

    Escárcega, Ricardo O / García-Carrasco, Mario / Mendoza-Pinto, Claudia

    Reumatologia clinica

    2020  Band 16, Heft 5 Pt 1, Seite(n) 311–312

    Mesh-Begriff(e) Atherosclerosis/etiology ; Atherosclerosis/prevention & control ; Autoimmune Diseases/complications ; Autoimmune Diseases/therapy ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/prevention & control ; Humans ; Rheumatic Diseases/complications ; Rheumatic Diseases/therapy
    Sprache Spanisch
    Erscheinungsdatum 2020-07-25
    Erscheinungsland Spain
    Dokumenttyp Editorial
    ISSN 2173-5743
    ISSN (online) 2173-5743
    DOI 10.1016/j.reuma.2020.07.001
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant).

    Mendoza-Pinto, Claudia / García-Carrasco, Mario / Cervera, Ricard

    Current rheumatology reports

    2018  Band 20, Heft 10, Seite(n) 62

    Abstract: ... in viral infections. The most frequent infection related to aPL has been hepatitis C virus. These antibodies may be ...

    Abstract Purpose of review: The antiphospholipid syndrome (APS) is characterized by the development of thrombotic events and pregnancy morbidity in the presence of antiphospholipid antibodies (aPL). An infectious etiology for this syndrome has been postulated. The present review is aimed to summarize recent evidence about the role of infections and vaccines in the pathogenesis of the APS (including its catastrophic variant).
    Recent findings: There is an increased risk of developing aPL in various infections, particularly in viral infections. The most frequent infection related to aPL has been hepatitis C virus. These antibodies may be associated with thromboembolic events, including catastrophic APS. There is a link between vaccinations, such as the tetanus toxoid and aPL, due to molecular mimicry between the two molecules. Accumulated evidence supports that the presence of aPL is associated with a variety of infections, including viruses, bacteria, fungi, and parasites, and the main mechanism to explain this correlation is molecular mimicry. Moreover, a link between vaccinations, such as the tetanus toxoid, and APS has also been described.
    Mesh-Begriff(e) Antiphospholipid Syndrome/virology ; Bacterial Infections/complications ; Hepatitis C/complications ; Humans ; Tetanus/complications ; Virus Diseases/complications
    Sprache Englisch
    Erscheinungsdatum 2018-08-20
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2057357-1
    ISSN 1534-6307 ; 1523-3774
    ISSN (online) 1534-6307
    ISSN 1523-3774
    DOI 10.1007/s11926-018-0773-x
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Low disease activity state associated with fewer incident vertebral fractures in Mestizo women with systemic lupus erythematosus.

    Mendoza-Pinto, Claudia / Etchegaray-Morales, Ivet / Munguía-Realpozo, Pamela / Osorio-Peña, Ángel David / Méndez-Martínez, Socorro / Ramírez-Lara, Edith / Zárate-Arellano, Diana / Solis-Poblano, Juan Carlos / Ayón-Aguilar, Jorge / García-Carrasco, Mario

    Lupus

    2023  Band 32, Heft 11, Seite(n) 1328–1334

    Abstract: Background: Low disease activity state (LDAS) has been linked to a significant reduction in flares and damage accrual in patients with systemic lupus erythematosus (SLE); however, the effect of LDAS on the risk of vertebral fractures (VFs) in subjects ... ...

    Abstract Background: Low disease activity state (LDAS) has been linked to a significant reduction in flares and damage accrual in patients with systemic lupus erythematosus (SLE); however, the effect of LDAS on the risk of vertebral fractures (VFs) in subjects with SLE is unknown, considering that low bone mineral density (BMD) and VF are frequent in SLE.
    Objective: to evaluate whether achieving LDAS ≥50% of the observation time prevents new VF and BMD changes in Mestizo women.
    Methods: We carried out a longitudinal, observational, and retrospective study. Mestizo women with SLE were included for a median of an 8-year follow-up. LDAS was described as Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≤4, prednisone ≤7.5 mg/day, and stable immunosuppressive therapies. BMD measurements and lateral thoracic and lumbar radiographs for a semiquantitative analysis for VF were assessed at baseline and during the follow-up. Uni- and multivariable interval-censored survival regression models were carried out.
    Results: We included 110 patients: 35 (31.8%) had new VF. A total of 56 patients (50.1%) achieved LDAS ≥50% of the time during the follow-up and achieved a significantly lesser risk of incident VF (HR = 0.16; 95% CI, 0.06-0.49). After adjusting by age, BMI, menopause, prevalent VF, baseline BMD, cumulative glucocorticoid use, and anti-osteoporotic therapy, LDAS-50 was significantly related to a decrease in the risk of a new VF (HR = 0.39; 95% CI, 0.16-0.98). There was no association between LDAS and BMD measurement changes. When only patients on LDAS but not in remission (
    Conclusions: LDAS ≥50% of the time was significantly associated with a diminished risk of new VF in Mestizo women with SLE, even in patients not in remission. However, LDAS did not help modify BMD changes over time.
    Mesh-Begriff(e) Female ; Humans ; Bone Density ; Glucocorticoids/therapeutic use ; Lupus Erythematosus, Systemic/complications ; Lupus Erythematosus, Systemic/drug therapy ; Prednisone/therapeutic use ; Retrospective Studies ; Spinal Fractures/diagnostic imaging ; Spinal Fractures/epidemiology
    Chemische Substanzen Glucocorticoids ; Prednisone (VB0R961HZT)
    Sprache Englisch
    Erscheinungsdatum 2023-09-13
    Erscheinungsland England
    Dokumenttyp Journal Article ; Observational Study
    ZDB-ID 1154407-7
    ISSN 1477-0962 ; 0961-2033
    ISSN (online) 1477-0962
    ISSN 0961-2033
    DOI 10.1177/09612033231202878
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang